Trials / Not Yet Recruiting
Not Yet RecruitingNCT07527832
An Observational Study to Learn About the Medicine - BEVACIZUMAB BS [Pfizer] in Colorectal Cancer Patients From Japan.
BEVACIZUMAB BS Intravenous Infusion 100mg, 400mg [Pfizer] Post-Marketing Database Study
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (estimated)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 15 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to look at the safety of BEVACIZUMAB BS \[Pfizer\] when it was used to colorectal cancer patients in real-world clinical setting in Japan. The study population includes individuals who have a diagnosis of colorectal cancer and have been treated with Bevacizumab-Pfizer Biosimilar or Avastin between 1 December 2019 and 30 November 2024. Data source is the Medical Data Vision (MDV) database - a hospital-based claims database in Japan.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bevacizumab-Pfizer Biosimilar | As provided in real world practice |
| DRUG | Avastin | As provided in real world practice |
Timeline
- Start date
- 2026-05-01
- Primary completion
- 2026-05-31
- Completion
- 2026-05-31
- First posted
- 2026-04-14
- Last updated
- 2026-04-14
Source: ClinicalTrials.gov record NCT07527832. Inclusion in this directory is not an endorsement.